Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma

Updates on induction chemotherapy for locally advanced squamous cell carcinoma were an important part of the wider discussion on treatment sequencing at the 17th World Congress for Esophageal Diseases. Hosted virtually by the International Society for Diseases of the Esophagus from 27–30 September 2021, ISDE 2021 brought together specialists examining systemic therapy, radiotherapy, surgery, staging and multidisciplinary care.

For Australian clinicians, the topic is particularly relevant because oesophageal squamous cell carcinoma can present with advanced disease, nutritional compromise and substantial treatment-related risk. Decisions must account for tumour stage, resectability, performance status, access to high-volume upper gastrointestinal services and the practical realities of care across metropolitan and regional Australia.

Why Induction Treatment Is Being Reconsidered

Induction chemotherapy refers to systemic treatment given before the main local therapy, which may be chemoradiotherapy, surgery or definitive radiation-based treatment. The proposed advantages include early treatment of micrometastatic disease, tumour shrinkage, improved swallowing and a clearer indication of whether the cancer is biologically sensitive to chemotherapy.

For squamous cell carcinoma, the established treatment pathway remains highly dependent on stage and treatment intent. Some patients proceed to neoadjuvant chemoradiotherapy followed by oesophagectomy, while others receive definitive chemoradiotherapy because surgery is unsuitable or unlikely to improve outcomes. Induction chemotherapy is generally considered an additional strategy rather than a universal replacement for these approaches.

The evidence has been driven by phase II studies, retrospective series and institutional experience rather than one definitive global standard. Patient selection is therefore central. A regimen that may be reasonable for a fit patient with bulky, potentially resectable disease could be unsafe for someone with weight loss, renal impairment or poor baseline function.

What Recent Evidence Suggests

Studies presented and discussed around the 2021 congress period explored multi-agent chemotherapy before chemoradiotherapy or surgery. Commonly investigated combinations included platinum-based therapy with a fluoropyrimidine or a taxane. Some reports suggested higher clinical response, improved control of distant disease and a greater chance of completing subsequent local treatment.

These signals need careful interpretation. Retrospective studies may favour induction treatment because patients selected for it are often younger, fitter and treated in experienced centres. Additional chemotherapy can also delay surgery or definitive radiotherapy, increase neutropenia and worsen nutritional decline. A radiological response does not necessarily indicate complete eradication of viable tumour.

The key unanswered question is whether better response rates translate into longer overall survival without compromising the curative treatment that follows. Randomised comparisons remain more persuasive than single-centre outcomes, particularly when treatment schedules, radiation doses and surgical expertise vary between health systems.

Selecting Patients in Australian Practice

Australian upper gastrointestinal teams commonly review staging with contrast CT, PET-CT and endoscopy, with endoscopic ultrasound used selectively. Histological confirmation of squamous differentiation, assessment of nodal disease and evaluation for distant metastases are essential before discussing induction treatment. A dietitian, speech pathologist and specialist nurse can be important when dysphagia or aspiration affects treatment readiness.

The treatment plan should also reflect whether care is delivered through a public hospital, private practice or a shared arrangement. Patients in Sydney, Melbourne, Brisbane and Perth may have relatively direct access to specialist centres and clinical trials, while people travelling from regional New South Wales, Queensland, Western Australia or the Northern Territory may face accommodation, transport and time-away-from-work pressures.

Aboriginal and Torres Strait Islander patients may experience additional barriers related to distance, continuity of care and culturally safe communication. Early involvement of Aboriginal health workers, family supports and local services can help make an intensive treatment sequence more workable.

Practical Signals Before Starting Therapy

The decision to use induction chemotherapy should be documented within a multidisciplinary discussion. It should distinguish between a planned evidence-based sequence, a clinical trial and an individualised approach used because of tumour bulk or symptoms. Australian prescribing and funding conditions also matter: access to newer systemic agents depends on Therapeutic Goods Administration approval, Pharmaceutical Benefits Scheme arrangements and trial eligibility.

Useful factors to record include:

• Performance status, frailty and cardiopulmonary fitness
• Weight trend, dysphagia severity and nutritional intake
• Tumour length, nodal burden and suspected resectability
• Renal function, hearing, neuropathy and comorbidities

Treatment monitoring should focus on whether the patient remains fit enough for definitive local therapy. Re-staging may include CT, PET-CT, endoscopy or clinical assessment, depending on the protocol. A response should trigger a timely review rather than automatically prolonging chemotherapy.

Evidence should be checked against the treatment setting:

• Induction before chemoradiotherapy
• Induction before planned oesophagectomy
• Definitive treatment for unresectable disease
• A clinical trial involving immunotherapy or biomarker selection

The Role of Immunotherapy and Future Research

The modern treatment landscape is moving towards integration of immunotherapy with chemotherapy and chemoradiotherapy. Later evidence in oesophageal cancer has supported immune checkpoint inhibitors for selected advanced or residual disease settings, but this does not mean that immunotherapy can be routinely added to induction treatment for every patient with locally advanced squamous carcinoma.

Important research questions include the value of biomarkers, the best duration of induction therapy, the safety of combining immunotherapy with radiation and the use of pathological or metabolic response to guide surgery. Trials may also clarify whether treatment should be intensified for high-risk disease or reduced for patients with an early, deep response.

For Australian services, participation in cooperative group trials can help resolve these questions while giving patients access to carefully monitored regimens. The most reliable pathway remains coordinated care involving medical oncology, radiation oncology, upper gastrointestinal surgery, radiology, pathology, nursing and allied health.

The next concrete step is to present each eligible patient at the local upper gastrointestinal multidisciplinary team with complete staging, nutritional assessment, fitness measures and a clearly documented treatment intent.